Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
1557697-10-5 | 3-(4-fluoro-tetrahydro-2H-pyran-4-yl)benzaldehyde | AA019EI5 | MFCD26728754
1603111-54-1 | 3-(4-(TRIFLUOROMETHYL)PYRIDIN-3-YL)PROPANOIC ACID | AA019ELB | MFCD31555241
100956-66-9 | N-(3,4-dimethoxyphenyl)-4-methylbenzenesulfonamide | AA019EOL | MFCD00666395
1698027-00-7 | tert-butyl 4-(7-bromo-6-chloroquinazolin-4-yl)piperazine-1-carboxylate | AA019ERN | MFCD31555251
1823822-55-4 | Benzyl 3-(2-aminothiazol-4-yl)morpholine-4-carboxylate | AA019EUY | MFCD27997377
1101120-00-6 | 3-Ethyl 5-methyl pyrazolo[1,5-a]pyridine-3,5-dicarboxylate | AA019EY4 | MFCD20528906
102625-70-7 | Pantoprazole | AA019FQG | MFCD00870182
170111-34-9 | (E)-(3S)-3-Amino-4-phenyl-1-(phenylsulphonyl)but-1-ene hydrochloride | AA019FXY | MFCD09998739
379254-41-8 | 2-(4-fluoro-3-methylbenzenesulfonamido)benzoic acid | AA019GIA | MFCD03147247
80419-13-2 | 2-cyano-N-(4-phenoxyphenyl)acetamide | AA019GSL | MFCD03376769